Search results for "MAb"

showing 10 items of 1716 documents

Early Treatment of Systemic Juvenile Idiopathic Arthritis with Canakinumab and Complete Remission After 2 Years of Treatment Suspension: Case Report …

2019

Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease characterised by fever and arthritis. We describe the case of a 14-year-old girl hospitalised with fever associated with rash, myalgia, arthralgia and polyarticular involvement. Examinations revealed increased levels of C-reactive protein, erythrocyte sedimentation rate, ferritin, triglycerides, leukocytes, neutrophils, lactate dehydrogenase, fibrinogen, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT). Bone marrow biopsy showed polyclonal leukocyte activation. A genetic study revealed a heterozygous mutation of the MEFV gene, c.442G>C (E148Q), which is typical of…

myalgiaAbdominal painmedicine.medical_specialtyTime FactorsAdolescentCanakinumabFamilial Mediterranean feverArthritisCase Report030204 cardiovascular system & hematologyAntibodies Monoclonal Humanized030226 pharmacology & pharmacyGastroenterology03 medical and health sciences0302 clinical medicineautoinflammatory diseaseInternal medicinemedicineHumansPharmacology (medical)medicine.diagnostic_testbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineExanthemamedicine.diseaseMEFVRashdigestive system diseasesArthritis JuvenileCanakinumabTreatment OutcomeErythrocyte sedimentation rateSystemic juvenile idiopathic arthritiFemalemedicine.symptombusinessmedicine.drug
researchProduct

Open-label ODYSSEY APPRISE study: Interim data from the first 843 participants

2018

Background PCSK9 inhibitors (PCSK9i) have been recommended by the ESC/EAS Task Force in very high risk subjects with ASCVD and those with heterozygous familial hypercholesterolemia (HeFH) with persistent high LDL-C levels despite maximally tolerated LLT. Purpose ODYSSEY APPRISE (NCT02476006) is the first study to assess efficacy and safety at Week (W) 12 of the PCSK9i alirocumab (ALI) in a real-life setting prior to commercial availability. Methods APPRISE was an open-label, single-arm study, conducted in 16 European countries and Canada. Subjects with inadequately controlled lipid levels despite maximally tolerated LLT were included. Based on physician's judgment, participants received eit…

myalgiamedicine.medical_specialtyErythemabusiness.industryFamilial hypercholesterolemia030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineTolerabilityInternal medicineClinical endpointmedicineBack painmedicine.symptomCardiology and Cardiovascular MedicineAdverse effectbusiness030217 neurology & neurosurgeryAlirocumabArchives of Cardiovascular Diseases Supplements
researchProduct

Looking for the best therapeutical stretegy after the 24th natalizumab adiministretion. The TY-STOP study

2012

natalizumab multiple sclerosis
researchProduct

Capacidad predictiva y pronóstica de factores moleculares en cáncer de mama HER2 positivo tratado con quimioterapia neoadyuvante basada en antracicli…

2017

El tratamiento neoadyuvante del cáncer de mama (CM) permite estudiar marcadores subrogados que puedan predecir respuesta clínica y supervivencia. La respuesta completa patológica (RCp) definida como la ausencia de tumor infiltrante en la mama y axila en la pieza quirúrgica se asocia a mejor supervivencia. En los tumores HER2 positivo el tratamiento de elección es la combinación de quimioterapia, antraciclinas y taxanos son los esquemas con mayor evidencia, con terapia anti-HER2 (trastuzumab (TTZ)) alcanzando tasas de RCp del 30-60%. No disponemos de factores predictivos que identifiquen qué subgrupo obtendrá mayores tasas de RCp . Existe evidencia que los tumores con receptores hormonales (…

neoadyuvanciatrastuzumabPTENHER2UNESCO::CIENCIAS MÉDICAS ::Medicina del trabajo::Otrascancer de mama:CIENCIAS MÉDICAS ::Medicina del trabajo::Otras [UNESCO]PI3Kinfiltrado linfocitario
researchProduct

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer

2022

Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when chemotherapy is combined with monoclonal antibodies (bevacizumab, cetuximab, and panitumumab). Targeted therapy based on the use of anti-epidermal growth factor receptors (EGFRs) is conditioned by the potential for increased toxicity, making it more difficult to treat an older, rat sarcoma virus (RAS) and B rapidly accelerated fibrosarcoma (BRAF) wild-type patient. In light of a more detailed charac…

older patientmetastatic colorectal cancercetuximabpanitumumab.General Medicine
researchProduct

ISODECIMAL NUMBERS

2006

The aim of this paper is to investigate pairs of real numbers of the type $(x,\frac{1}{x}),$ \ $(x,\frac{a}{x})$ and $(x,x^{2}),$ where the first component is a real number $x\neq0$ and the fractional parts of the coordinates are equal. We call such numbers \textit{isodecimal}.

ophantine approximationHausdorff dimensionbadly approximable
researchProduct

Epidemiology, clinical manifestations, risk-reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agen…

2014

Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma. Available data suggest that 0–27.5% of individuals exposed to antiresorptive agents can develop ONJ. There is increasing evidence that avoidance of surgical trauma and infection to the jawbones can minimize the risk of ONJ, but there are still a significant number of individuals who develop ONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is no definitive cure for ONJ with the exclusion, in certain cases, of surgica…

osteonecrosibisphosphonatejawSettore MED/28 - Malattie Odontostomatologicheantiresorptive agentcancerdenosumabepidemiologymanagementrisk
researchProduct

Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single …

2022

Background: Medication-Related Osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction mainly associated to bone modifying agents (BMAs). Breast cancer (BC) is the most frequent cancer worldwide. Its therapy can cause cancer treatment-induced bone loss (CTIBL), commonly treated with BMAs. The aims of this retrospective study are: to describe characteristics of BC patients under BMAs for CTIBL; to record any switch to high-dose BMAs; to assess MRONJ onset and to identify any factors associated with it. Patients: Authors included patients referred for MRONJ prevention to the Unit of Oral Medicine (University Hospital of Palermo). Results: Fourteen female BC patients under low-dose BMAs f…

osteonecrosis of the jawbisphosphonatebreast cancerBPosteonecrosis of the jaw; MRONJ; cancer treatment-induced bone loss; CTIBL; breast cancer; osteoporosis; bone metastases; bisphosphonates; BPs; denosumabcancer treatment-induced bone loosteoporosidenosumabPharmacology (medical)MRONJCTIBLbone metastaseOral; Volume 2; Issue 4; Pages: 274-285
researchProduct

A case of osteonecrosis of the jaws in epidermolysis bullosa patient treated with rituximab.

2017

We report a case of a patient with EBA, who developed ONJ after Rituximab treatment.

osteonecrosis of the jawsepidermolysis bullosarituximab
researchProduct

Measurement and communication interfaces for distributed generation in smart grids

2013

The aim of this work is to perform a feasibility study on the measurement and communication strategies for the development of a new generation of interface devices for distributed generators and their integration on smart grids. The communication system can use one or more technologies, at the various levels, creating a low cost network infrastructure, in the framework of a SCADA (Supervisory Control and Data Acquisition) architecture. As regards the measurements, the attention is focused on the anti-islanding protection, based on a hybrid solution, which makes use of local measurements and communications with the grid, at both MV and LV level by employing the PLC technology. Some simulatio…

power line communicationEngineeringdistributed generationbusiness.industrydistributed generation interface devices smart grids power system communications power line communication islanding detectionInterface (computing)Programmable logic controllerCommunications systemGridpower system communicationsinterface devicesSmart gridSCADAEmbedded systemDistributed generationsmart grids.islanding detectionArchitecturebusinessSettore ING-INF/07 - Misure Elettriche E Elettroniche
researchProduct